세계의 임신성 융모성 질환 시장 보고서(2025년)

Gestational trophoblastic disease (GTD) encompasses a group of rare and abnormal conditions arising from the anomalous growth of trophoblastic cells, leading to the formation of a tumor within the uterus following conception. The treatment for GTD typically involves uterine evacuation and the ongoing monitoring of human chorionic gonadotropin (hCG) levels.

The main types of gestational trophoblastic disease include hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others. A hydatidiform mole, also referred to as a molar pregnancy, is an uncommon and abnormal pregnancy condition. Treatment options for this condition include surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy. These treatments are administered by various end-users such as hospitals, clinics, diagnostic centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The gestational trophoblastic disease market research report is one of a series of new reports from The Business Research Company that provides gestational trophoblastic disease market statistics, including gestational trophoblastic disease industry global market size, regional shares, competitors with a gestational trophoblastic disease market share, detailed gestational trophoblastic disease market segments, market trends and opportunities, and any further data you may need to thrive in the gestational trophoblastic disease industry. This gestational trophoblastic disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gestational trophoblastic disease market size has grown steadily in recent years. It will grow from $2.06 billion in 2024 to $2.16 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to public health initiatives, improved understanding of disease pathology, medical research and clinical trials, development of targeted therapies, shift in treatment protocols.

The gestational trophoblastic disease market size is expected to see strong growth in the next few years. It will grow to $2.63 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to healthcare infrastructure development, enhanced telemedicine and remote care, patient-centric care approaches, regulatory approvals for novel treatments, genomic and molecular studies. Major trends in the forecast period include shift towards personalized medicine, advancements in molecular diagnostics, focus on immunotherapies and targeted therapies, integration of digital health technologies, rising awareness and education programs.

The forecast of 5.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of methotrexate formulations and Human Chorionic Gonadotropin test kits(hCG test kits) sourced from India and Germany, exacerbating rare pregnancy complication management costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in abnormal pregnancies is expected to fuel the growth of the gestational trophoblastic disease market in the future. Abnormal pregnancies are those that deviate from the normal or expected trajectory and can pose risks to the health of both the mother and the fetus. In cases of abnormal pregnancies, such as molar pregnancies, the trophoblast forms a tumor instead of developing into a fetus, leading to gestational trophoblastic disease. For example, in May 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that in 2022, there were 251,377 abortions among women residing in England and Wales-the highest number since the introduction of the Abortion Act, representing a 17% increase from the previous year. Thus, the increase in abnormal pregnancies is driving the growth of the gestational trophoblastic disease market.

The anticipated rise in cigarette smoking is expected to drive the growth of the gestational trophoblastic disease market in the future. Cigarette smoking involves burning tobacco and inhaling the resulting smoke, which contains a range of harmful chemicals and toxins that can negatively impact various body systems. This practice may damage the DNA of trophoblastic cells, which are crucial for forming the placenta, potentially leading to abnormal cell growth and division, and resulting in gestational trophoblastic disease. For instance, in May 2022, the Australian Bureau of Statistics, a government agency in Australia, reported that the rate of daily smokers increased with age, reaching a peak of 13.6% in the 55-64 age group during the 2021-2022 period. Therefore, the increasing prevalence of cigarette smoking is contributing to the growth of the gestational trophoblastic disease market.

Major companies operating in the gestational trophoblastic disease market are introducing updated guidelines to enhance services. For instance, in May 2022, The Health Service Executive National Cancer Control Programme in Ireland launched an updated gestational trophoblastic disease guideline, aiming to provide comprehensive insights into diagnostic and management strategies. By reducing practice variation and improving the quality of care, these guidelines contribute to better outcomes for gestational trophoblastic disease patients.

Companies in the gestational trophoblastic disease market are innovating treatments, such as reproductive tissue preservation solutions, to offer reliable services. Reproductive tissue preservation solutions, preserving the viability of reproductive tissue, provide flexibility and control over family-building choices. For instance, in June 2022, Inception Fertility introduced HavenCryo, a long-term reproductive tissue and cryopreservation storage solution, allowing indefinite storage of eggs, sperm, and embryos. This solution proves beneficial for individuals diagnosed with gestational trophoblastic disease who need fertility preservation before undergoing treatments that may impact fertility.

Major companies operating in the gestational trophoblastic disease market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sun Pharmaceutical Industries Ltd., GSK PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Mylan N.V, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Perrigo Company PLC, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., Wockhardt Ltd., Natco Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Arog Pharmaceuticals Inc., Advenchen Laboratories LLC., Mendus AB, AB Science S.A.

Asia-Pacific was the largest region in the gestational trophoblastic disease market in 2022, and is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational trophoblastic disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the gestational trophoblastic disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The gestational trophoblastic disease market consists of revenues earned by entities by providing services such as gynecology services, oncology services, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gestational trophoblastic disease market also includes sales of medications, diagnostic tools, laboratory tests, methotrexate, etoposide, cyclophosphamide, and vincristine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gestational Trophoblastic Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gestational trophoblastic disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gestational trophoblastic disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gestational trophoblastic disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hydatidiform Mole; Choriocarcinoma; Placental-Site Trophoblastic Tumor; Epithelioid Trophoblastic Tumor; Other Types
• 2) By Treatment: Surgery; Chemotherapy; Suction Dilation And Curettage (D&C); Radiation Therapy
• 3) By End User: Hospital And Clinics; Diagnostic Centers; Other End Users
• Subsegments:
• 1) By Hydatidiform Mole: Complete Hydatidiform Mole; Partial Hydatidiform Mole
• 2) By Choriocarcinoma: Non-Metastatic Choriocarcinoma; Metastatic Choriocarcinoma
• 3) By Placental-Site Trophoblastic Tumor: PSTT With Normal Placentation; PSTT With Abnormal Placentation
• 4) By Epithelioid Trophoblastic Tumor: Epithelioid Trophoblastic Tumor With No Evidence Of Metastasis; Epithelioid Trophoblastic Tumor With Metastasis
• 5) By Other Types: Trophoblastic Tumor Of Unknown Origin; Non-Gestational Trophoblastic Neoplasia
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG; Novartis AG; Merck And Co. Inc.; Sun Pharmaceutical Industries Ltd.; GSK plc; Bristol-Myers Squibb Company; Sanofi S.A.; AstraZeneca plc; Eli Lilly and Company; Mylan N.V; Daiichi Sankyo Co. Ltd.; Eisai Co. Ltd.; Perrigo Company plc; Jiangsu Hengrui Medicine Co. Ltd.; Exelixis Inc.; Wockhardt Ltd.; Natco Pharma Ltd.; Blueprint Medicines Corporation; Array BioPharma Inc.; Deciphera Pharmaceuticals Inc.; Ono Pharmaceutical Co. Ltd.; Boston Biomedical Inc.; DNAtrix Inc.; Arog Pharmaceuticals Inc.; Advenchen Laboratories LLC.; Mendus AB; AB Science S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gestational Trophoblastic Disease Market Characteristics

3. Gestational Trophoblastic Disease Market Trends And Strategies

4. Gestational Trophoblastic Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Gestational Trophoblastic Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gestational Trophoblastic Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gestational Trophoblastic Disease Market Growth Rate Analysis
• 5.4. Global Gestational Trophoblastic Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gestational Trophoblastic Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gestational Trophoblastic Disease Total Addressable Market (TAM)

6. Gestational Trophoblastic Disease Market Segmentation

• 6.1. Global Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hydatidiform Mole
• Choriocarcinoma
• Placental-Site Trophoblastic Tumor
• Epithelioid Trophoblastic Tumor
• Other Types
• 6.2. Global Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Chemotherapy
• Suction Dilation And Curettage (D&C)
• Radiation Therapy
• 6.3. Global Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital And Clinics
• Diagnostic Centers
• Other End Users
• 6.4. Global Gestational Trophoblastic Disease Market, Sub-Segmentation Of Hydatidiform Mole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complete Hydatidiform Mole
• Partial Hydatidiform Mole
• 6.5. Global Gestational Trophoblastic Disease Market, Sub-Segmentation Of Choriocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Metastatic Choriocarcinoma
• Metastatic Choriocarcinoma
• 6.6. Global Gestational Trophoblastic Disease Market, Sub-Segmentation Of Placental-Site Trophoblastic Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PSTT With Normal Placentation
• PSTT With Abnormal Placentation
• 6.7. Global Gestational Trophoblastic Disease Market, Sub-Segmentation Of Epithelioid Trophoblastic Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epithelioid Trophoblastic Tumor With No Evidence Of Metastasis
• Epithelioid Trophoblastic Tumor With Metastasis
• 6.8. Global Gestational Trophoblastic Disease Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trophoblastic Tumor Of Unknown Origin
• Non-Gestational Trophoblastic Neoplasia

7. Gestational Trophoblastic Disease Market Regional And Country Analysis

• 7.1. Global Gestational Trophoblastic Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gestational Trophoblastic Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gestational Trophoblastic Disease Market

• 8.1. Asia-Pacific Gestational Trophoblastic Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gestational Trophoblastic Disease Market

• 9.1. China Gestational Trophoblastic Disease Market Overview
• 9.2. China Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gestational Trophoblastic Disease Market

• 10.1. India Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gestational Trophoblastic Disease Market

• 11.1. Japan Gestational Trophoblastic Disease Market Overview
• 11.2. Japan Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gestational Trophoblastic Disease Market

• 12.1. Australia Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gestational Trophoblastic Disease Market

• 13.1. Indonesia Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gestational Trophoblastic Disease Market

• 14.1. South Korea Gestational Trophoblastic Disease Market Overview
• 14.2. South Korea Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gestational Trophoblastic Disease Market

• 15.1. Western Europe Gestational Trophoblastic Disease Market Overview
• 15.2. Western Europe Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gestational Trophoblastic Disease Market

• 16.1. UK Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gestational Trophoblastic Disease Market

• 17.1. Germany Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gestational Trophoblastic Disease Market

• 18.1. France Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gestational Trophoblastic Disease Market

• 19.1. Italy Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gestational Trophoblastic Disease Market

• 20.1. Spain Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gestational Trophoblastic Disease Market

• 21.1. Eastern Europe Gestational Trophoblastic Disease Market Overview
• 21.2. Eastern Europe Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gestational Trophoblastic Disease Market

• 22.1. Russia Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gestational Trophoblastic Disease Market

• 23.1. North America Gestational Trophoblastic Disease Market Overview
• 23.2. North America Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gestational Trophoblastic Disease Market

• 24.1. USA Gestational Trophoblastic Disease Market Overview
• 24.2. USA Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gestational Trophoblastic Disease Market

• 25.1. Canada Gestational Trophoblastic Disease Market Overview
• 25.2. Canada Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gestational Trophoblastic Disease Market

• 26.1. South America Gestational Trophoblastic Disease Market Overview
• 26.2. South America Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gestational Trophoblastic Disease Market

• 27.1. Brazil Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gestational Trophoblastic Disease Market

• 28.1. Middle East Gestational Trophoblastic Disease Market Overview
• 28.2. Middle East Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gestational Trophoblastic Disease Market

• 29.1. Africa Gestational Trophoblastic Disease Market Overview
• 29.2. Africa Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gestational Trophoblastic Disease Market Competitive Landscape And Company Profiles

• 30.1. Gestational Trophoblastic Disease Market Competitive Landscape
• 30.2. Gestational Trophoblastic Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Gestational Trophoblastic Disease Market Other Major And Innovative Companies

• 31.1. Merck And Co. Inc.
• 31.2. Sun Pharmaceutical Industries Ltd.
• 31.3. GSK plc
• 31.4. Bristol-Myers Squibb Company
• 31.5. Sanofi S.A.
• 31.6. AstraZeneca plc
• 31.7. Eli Lilly and Company
• 31.8. Mylan N.V
• 31.9. Daiichi Sankyo Co. Ltd.
• 31.10. Eisai Co. Ltd.
• 31.11. Perrigo Company plc
• 31.12. Jiangsu Hengrui Medicine Co. Ltd.
• 31.13. Exelixis Inc.
• 31.14. Wockhardt Ltd.
• 31.15. Natco Pharma Ltd.

32. Global Gestational Trophoblastic Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gestational Trophoblastic Disease Market

34. Recent Developments In The Gestational Trophoblastic Disease Market

35. Gestational Trophoblastic Disease Market High Potential Countries, Segments and Strategies

• 35.1 Gestational Trophoblastic Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gestational Trophoblastic Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gestational Trophoblastic Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer